
As many as 116 companies are set to see their anchor investor lock-in periods expire between November 9, 2026 and February 26, 2027, involving shares valued at approximately $35 billion. According to Nuvama Alternative & Quantitative Research, the upcoming expiries cover companies listed up to November 5, 2026, with the proportion of shares becoming eligible ranging from around 13% to 67% of their respective total equity. The releases could bring a sizeable portion of previously locked-in shares into the tradable pool, although expiry does not necessarily mean that investors will sell their holdings. The unlocking of shares does not necessarily mean anchor investors will sell their holdings. However, the additional supply could influence near-term stock movements depending on investor decisions and market demand.
The market performance of the November 2026 group shows strong results, with Zetwerk Manufacturing Business leading with 75 million shares (4% of total equity) becoming eligible for trading. According to Nuvama's latest research, Sahajanand Medical Technologies has 2 million shares (2%) scheduled for unlock, while Bonfiglioli Transmissions will see 6 million shares (3%) released. Tonbo Imaging India has 2 million shares (3%) scheduled for release on the same date. In the National Stock Exchange category, 1 million shares (0.1%) will become eligible for trading. The 30-day group performance remains positive with all 11 stocks trading above their respective IPO issue prices, as previously reported by PL Capital.
The November 23-December 2 period features significant unlocks including Tempsens Instruments (India)* with 3 million shares (4%) and Gaja Alternative Asset Management with 5 million shares (4%) on November 23. On November 25, Paras Healthcare has 5 million shares (4%) and Jio Platforms has 36 million shares (0.4%) due to become eligible for trading. Acevector has 2 million shares (0.4%) and Augmont Enterprises has 2 million shares (2%) for November 25. The November 26 schedule includes Hy-Tech Engineers with 4 million shares (4%), Skyways Air Services with 6 million shares (4%), and Symbiotec Pharmalab with 3 million shares (4%). The November 30 schedule features SFC Environmental Technologies with 3 million shares (3%) and BLS Polymers with 3 million shares (4%).
Jio Platforms shares have climbed over 26% from their IPO issue price of ₹1,119, with the stock opening at ₹1,399.70 on BSE and touching an intraday high of ₹1,413.95 per share. The company reported strong Q2 FY27 results with consolidated net profit rising 13.7% year-on-year to ₹8,389 crore and revenue from operations growing 11.4% to ₹40,475 crore. According to LiveMint, the performance was supported by subscriber additions, improved realisations per user and healthy growth in digital services. Managing Director Akash Ambani highlighted the strength of Jio's 5G network and expanding broadband and digital services reach. The company has utilized ₹27,500 crore of IPO proceeds to prepay external commercial borrowings of subsidiary Reliance Jio Infocomm. Gaurav Garg from Lemonn recommends existing investors hold with a medium- to long-term horizon, while fresh buyers should avoid chasing the rally and consider staggered accumulation during market corrections.
The January 2027 schedule includes significant unlocks with SBI Funds Management featuring 1,428 million shares (70% of outstanding equity) on January 18, representing the largest single unlock in the extended timeline. Other notable January entries include CSM Technologies with 28 million shares (55%) on January 4, Aastha Spintex with 11 million shares (25%) on January 5, and Knack Packaging with 43 million shares (35%) on January 11. The February 2027 schedule runs through February 26, featuring Manipal Health Enterprises with 344.7 million shares (26%) on February 4 and INDO-MIM with 286.2 million shares (58%) on February 8. Nuvama's analysis notes that while lock-in expiry means shares become eligible for trading, it does not guarantee actual selling by shareholders, and a sizeable portion of unlocked shares is held by promoters and promoter groups. The research firm emphasizes that investors should assess the scale of each scheduled unlock but cannot determine actual trading volumes.